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Abstract
Background: Animals from the same litter are often more alike compared with animals from different litters.
This litter-to-litter variation, or “litter effects”, can influence the results in addition to the experimental factors
of interest. Furthermore, an experimental treatment can be applied to whole litters rather than to individual
offspring. For example, in the valproic acid (VPA) model of autism, VPA is administered to pregnant females
thereby inducing the disease phenotype in the offspring. With this type of experiment the sample size is the
number of litters and not the total number of offspring. If such experiments are not appropriately designed and
analysed, the results can be severely biased as well as extremely underpowered.
Results: A review of the VPA literature showed that only 9% (3/34) of studies correctly determined that the
experimental unit (n) was the litter and therefore made valid statistical inferences. In addition, litter effects
accounted for up to 61% (p <0.001) of the variation in behavioural outcomes, which was larger than the treatment
effects. In addition, few studies reported using randomisation (12%) or blinding (18%), and none indicated that
a sample size calculation or power analysis had been conducted.
Conclusions: Litter effects are common, large, and ignoring them can make replication of findings difficult and
can contribute to the low rate of translating preclinical in vivo studies into successful therapies. Only a minority
of studies reported using rigorous experimental methods, which is consistent with much of the preclinical in vivo
literature.
Key words: Autism, Experimental design, Litter-effects, Mixed-effects model, Multiparous, Nested model, Valproic
acid
Background
Numerous animal models (lesion, transgenic, knock-
out, selective breeding, etc.) have been developed
for a variety of psychiatric, neurodegenerative, and
neurodevelopmental disorders. While many of these
models have been helpful for understanding disease
pathology, they have been less useful for discover-
ing potential therapies or predicting clinical efficacy.
Translation from in vivo animal models (typically
rodent) has been poor, despite many years of re-
search and effort. There are many reasons for this,
including the inherent difference in biology between
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rodents and humans [1], particularly relating to
higher cognitive functions. In addition, there is the
ever-present question of whether a particular animal
model is even suitable; whether it recapitulates the
disease process of interest or faithfully mimics key
aspects of the human condition. While important,
these two considerations will be put aside and the
focus will be on the design and analysis of preclini-
cal studies using multiparous species, and how this
affects the validity and reproducibility of results.
There are two issues that will be discussed. The
first deals with designs where an experimental treat-
ment is applied to whole litters rather than to the
individual animals, usually because the treatment
is applied to pregnant females and therefore to all
of the offspring. The second is the natural litter-to-
litter variation that is often present, which means
that the value of a measured experimental outcome
can potentially be influenced by the litter that the
animal came from.
Applying treatments to whole litters
Some disease models have a distinctive experimental
design feature: the treatment is applied to pregnant
females (and therefore to all of the unborn animals
within that female), but the scientific interest is in
the individual offspring (Figure 1). Here, the “treat-
ment” refers to the experimental manipulation that
induces the disease features, and it does not refer
to a therapeutic treatment. This design is com-
mon in toxicology and nutrition studies, but is also
used in neuroscience studies when examining the
effects of maternal stress and in the valproic acid
(VPA) model of autism. Difficulties arise because
the experimental unit (“n”; defined as the smallest
physical unit that can be randomly assigned to a
treatment condition) is the pregnant dam and not
the individual offspring [2–12]. In other words, the
sample size is the number of dams, and the offspring
are considered subsamples, much like the left and
right kidney from a single animal do not represent
a sample size of two (n = 1, even though there are
two “repeated” measurements). This may come as
a surprise, and it is irrelevant that the scientific
interest is in the offspring, or that the offspring
eventually become individual entities (unlike kid-
neys). Regulatory authorities have clear guidelines
on the matter [13, 14]; for example, the Organisa-
tion for Economic Co-operation and Development
(OECD) has made a firm statement in their guide-
lines for chemical testing: “Developmental studies
using multiparous species where multiple pups per
litter are tested should include the litter in the sta-
tistical model to guard against an inflated Type I
error rate. The statistical unit of measure should
be the litter and not the pup. Experiments should
be designed such that litter-mates are not treated
as independent observations [p. 12]” [14]. There is
a restriction on randomisation because only whole
litters can be assigned to the treatment or control
conditions, which has implications for how studies
are designed and analysed. An appropriate analysis
can be conducted by using only one animal per litter
(randomly selected), which allows standard methods
to be used (e.g. t-test, ANOVA, etc.). This is often
not the most efficient design in terms of animal us-
age, unless the excess animals can be used for other
experiments. A second option is to use more than
one animal per litter, and then average the values of
the animals within a litter. These mean values can
then be taken forward and analysed using standard
methods. A third option is to use multiple ani-
mals per litter, and then use a mixed-effects model
for analysis, which properly handles the structure
of the data (i.e. animals are nested within litters)
and avoids artificially inflating the sample size (also
known as pseudoreplication [12, 15]). The third
method is preferred to averaging values within a lit-
ter because the magnitude of the litter effect can be
quantified. In addition, information on the precision
of estimates will be lost by averaging, but is retained
and made use of in the mixed-effects model. When
using the first two options, it is clear that to increase
the sample size and thus power, the number of litters
needs to be increased. This is also true for the third
option, but may not be so readily apparent [10, pp.
3–4], and is discussed further below.
A related design issue is that greater statistical
power can be achieved when litter-mates are used
to test a therapeutic compound versus a placebo. If
the therapeutic treatment is applied to the individ-
ual animals postnatally, then the individual animal
is the experimental unit for this comparison. This
is referred to as a split-plot design and has more
than one type of experimental unit: litters for some
comparisons and individual animals for others [10].
These studies therefore require careful planning and
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analysis, but biologists are rarely introduced to these
designs and how to appropriately analyse data de-
rived from them during the course of their training.
Litter effects are ubiquitous, large, and important
It is known that for many measurable character-
istics across many species, monozygotic twins are
more similar than dizygotic twins, which are more
similar than non-twin siblings, and which in turn are
more similar than two unrelated individuals. What
has not been fully appreciated is that all of the
standard statistical methods (e.g. t-test, ANOVA,
regression, non-parametric methods) assume that
the data come from unrelated individuals. However,
rodents from the same litter are effectively dizygotic
twins; they are genetically very similar and share
prenatal and early postnatal environments. There-
fore, studies need to be designed and analysed in
such a way that if differences between litters exist,
they do not bias or confound the results [2–12]. More
specifically, this relates to the assumption of inde-
pendence of observations. For example, measuring
blood pressure (BP) from the left and right arm of
ten unrelated people only provides ten independent
measurements of BP, not twenty. This is because the
left and right BP values will be highly correlated—if
the BP value measured from a person’s left arm is
high, then so will the value measured from their
right arm. Similarly, two animals from the same lit-
ter will tend to have values that are more alike (i.e.
correlated) than two animals from different litters.
One can think of it as within-litter homogeneity
and between-litter heterogeneity. This lack of inde-
pendence needs to be handled appropriately in the
analysis and the three strategies outlined in the pre-
vious section can be used. Many animal models are
derived from highly inbred strains, and this results
in reduced genotypic and phenotypic variation. This
is a different issue and unrelated to lack of indepen-
dence. It does not mean that animals “are all the
same” and that differences between litters do not
exist.
Litter effects are not a minor issue that only
statistical pedants worry about with little practi-
cal importance for scientists. Using actual body
weight data from their experiment, Holson and
Pearce showed that if three “treated” and three
“control” litters are used, with two offspring per lit-
ter (total number of offspring = 12), then the false
positive rate (Type I error) is 20% rather than the
assumed 5% [4]. The false positive rate was deter-
mined as the proportion of p-values that fell below
0.05. Since there was no actual treatment applied,
random sampling should produce only a 5% error
rate. Furthermore, they showed that the false posi-
tive rate increases with the number of offspring per
litter; if the number of offspring per litter is 12 (to-
tal number of offspring = 72) then the false positive
rate is 80%. The error rate is also influenced by the
relative variability between and within litters and
will therefore vary for each experimental outcome.
Given that papers report the results of multiple tests
(multiple outcome variables and multiple compar-
isons), we can expect the literature to contain many
false positive results. It may seem paradoxical, but
in addition to an increased false positive rate, ig-
noring litter-to-litter variation can also lead to low
power (too many false negatives) when true effects
exist [4,5]. This occurs because litter-to-litter varia-
tion is unexplained variation, and thus the “noise” in
the data is increased, potentially masking true treat-
ment effects. A subsequent study using forty litters
found “significant litter effects. . . in varying degrees,
for almost every behavioural, morphologic, and neu-
roendocrine measure; they were evident across in-
dices of neural, adrenal, thyroid, and immunologic
functioning in adulthood” [5] (and see references
therein for further studies supporting this conclu-
sion). Holson and Pearce reported that only 30%
of papers in the behavioural neurotoxicology liter-
ature correctly accounted for litter effects [4] and
Zorrilla noted that 34% of papers in Developmental
Psychobiology and 15% of papers in related jour-
nals correctly accounted for litter effects [5]. This
issue has been discussed repeatedly for almost forty
years [2], but experimental biologists seem unaware
(or choose to ignore) the importance of dealing with
litter effects. One can only speculate on the number
of erroneous conclusions that have been reached and
the resources that have been wasted.
One might argue that when many studies are
conducted, including replications within and be-
tween labs, the evidence will eventually converge
to the “truth”, and therefore these considerations
are only of minor interest. Unfortunately, there
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is no guarantee of such convergence, as the litera-
ture on the superoxide dismutase (SOD1) transgenic
mouse model of amyotrophic lateral sclerosis (ALS)
demonstrates. Several treatments showed efficacy
in this model and were advanced to clinical trials,
where they proved to be ineffective [16]. A subse-
quent large-scale and properly executed replication
study did not support the previous findings [17].
This study also identified litter as an important
variable that affected survival (the main outcome)
and which was not taken into account in the earlier
studies. The authors also demonstrated how false
positive results can arise with inappropriate experi-
mental designs and analyses. Litter effects were not
the only contributing factor; a meta-analysis of the
preclinical SOD1 literature revealed that only 31%
of studies reported randomly assigning animals to
treatment conditions and even fewer reported blind
assessment of outcomes [18]. Lack of randomisation
and blinding are known to overstate the size of treat-
ment effects [19–23]. In addition, there was evidence
of publication bias, where studies with positive re-
sults were more likely to be published [18]. Thus,
the combination of poor experimental design, anal-
ysis, and publication bias contributed to numerous
incorrect decisions regarding treatment efficacy.
General quality of preclinical animal studies
Previous studies have shown that the general qual-
ity of the design, analysis, and interpretation of
preclinical animal experiments is low [20,21,23–30].
For example, Nieuwenhuis et al. recently reported
that 50% of papers in the neuroscience literature
misinterpret interaction effects [31]. In addition, the
issue of “inflated n”, or pseudoreplication, shows
up in other guises [12, 32], and whole fields can
misattribute cause-and-effect relationships [33, 34].
There is also the concept of “researcher degrees of
freedom”, which refers to the post hoc flexibility
in choosing the main outcome variables, statisti-
cal models, data transformations, how outliers are
handled, when to stop collecting data, and what
is reported in the final paper [35]. Various per-
mutations of the above options greatly increases
the chances that something statistically significant
can be found, and this gets reported as the sole
analysis that was conducted. Given the above con-
cerns, it is not surprising that the pharmaceutical
industry has difficulty reproducing many published
results [36–39].
Methods
Literature review
Ninety-five papers were identified on PubMed us-
ing the search term “(VPA [tiab] OR ‘valproic acid’
[tiab]) AND autism [tiab]” (up to the end of 2011).
Reference lists from these articles were then exam-
ined for further relevant studies, and one was found.
Only primary research articles that injected preg-
nant dams with VPA and subsequently analysed
the effects in the offspring were selected (in vitro
studies were excluded). A total of thirty-five studies
were found, and one was excluded as key informa-
tion was located in the supplementary material, but
this was not available online [40]. Two key pieces of
information were extracted: (1) whether the analy-
sis correctly identified the experimental unit as the
litter and (2) whether important features of good
experimental design were mentioned, including ran-
domisation, blinding, sample size calculation, and
whether the total sample size (i.e. number of preg-
nant dams) was indicated or could be determined.
Estimating the importance of litter-to-litter varia-
tion
Data from Mehta et al. [41] were used to estimate
the magnitude of differences between litters on a
number of outcome variables. This study was cho-
sen because it included animals from fourteen litters
(five saline, nine VPA) and therefore it was possible
to get a reasonable estimate of the litter-to-litter
variation. In addition, the study mentioned using
randomisation and blind assessment of outcomes.
Half of the animals in each condition were also
given MPEP (2-methyl-6-phenylethyl-pyrididine),
a metabotropic glutamate receptor 5 antagonist. To
assess the magnitude of the litter effects, the effect
of VPA, MPEP, and sex (if relevant) were removed,
and the remaining variability in the data that could
be attributed to differences between litters was esti-
mated. More specifically, models with and without
a random effect of litter were compared with a likeli-
4
hood ratio test. This analysis is testing whether the
variance between litters is zero, and it is known that
p-values will be too large because of “testing on the
boundary”, and so the simple method of dividing
the resulting p-values by two was used as recom-
mended by Zuur et al [42]. The exact specification
of the models is provided as R code in Additional
File 1 and the data are provided in Additional File 2.
Power analysis
In these types of designs, power (the ability to detect
an effect that is actually present) is influenced by (1)
the number of litters, (2) variability between litters,
(3) number of animals within litters, (4) variability
of animals within litters, (5) difference between the
means of the treatment groups (effect size), (6) sig-
nificance cutoff (traditionally α = 0.05), and (7) the
statistical test used. In order to illustrate the impor-
tance of the number of litters relative to the number
of animals within litters and how an inappropriate
analysis can lead to p-values that are too small, a
power analysis was conducted with the number of
litters per group varying from three to ten, and the
number of animals per litter varying from one to
ten. The other factors were held constant. Variabil-
ity between litters (SD = 0.8803) and the variability
of animals within litters (SD = 0.8142) was esti-
mated from the locomotor activity data from Mehta
et al. [41]. For each combination of litters and an-
imals, 5000 simulated datasets were created with a
mean difference between groups of 0.15. Once the
datasets were generated, the power for three types
of analyses were calculated. The first analysis av-
eraged the values of the animals within each litter
and then groups were compared with a t-test. The
second analysis used a mixed-effects model, and the
third ignored litter and compared all of the values
with a t-test. The last analysis is incorrect and only
presented to demonstrate how artificially inflating
sample size affects power. The power for each anal-
ysis was determined as the proportion of tests that
had p < 0.05. The R code is provided in Additional
File 1 and is adapted from Gelman and Hill [43].
Results and Discussion
Low quality of the published literature
The VPA model of autism is relatively new and po-
tential therapeutic compounds tested in this model
have not yet advanced to human trials. The op-
portunity therefore exists to clean up the literature
and prevent a repeat of the SOD1 story. The main
finding is that only 9% (3/34) of studies correctly
identified the experimental unit and thus made valid
inferences from the data. One study used a nested
design [44], the second mentioned that litter was the
experimental unit [45], and the third used one ani-
mal from each litter, thus bypassing the issue [46].
In fourteen studies (41%) it was not possible to de-
termine the number of dams that were used (i.e. the
sample size) and in four studies (12%) the number of
offspring used were not indicated. In addition, only
four (12%) reported randomly assigning pregnant
females to the VPA or control group. Many studies
also used only a subset of the offspring from each lit-
ter, but often it was not mentioned how the offspring
were selected. Only six studies (18%) reported that
the investigator was blind to the experimental con-
dition when collecting the data. Ten studies (29%)
did not indicate whether both male and female off-
spring were used. No study mentioned performing a
power analysis to determine a suitable sample size
to detect effects of a given magnitude—but this is
probably fortuitous, given that only three studies
correctly identified the experimental unit. It is pos-
sible that many studies did use randomisation and
assess outcomes blindly, but simply did not report
it. However, randomisation and blinding are cru-
cial aspects for the validity of the results and their
omission in manuscripts suggests that they were not
used. This is further supported by studies showing
that when manuscripts do not mention using ran-
domisation or blinding the estimated effects sizes are
larger compared to studies that do mention using
these methods, which is suggestive of bias [19–23,29].
A number of papers had additional statistical
or experimental design issues, ranging from trivial
(e.g. reporting total degrees of freedom rather than
residual degrees of freedom for an F-statistic) to
serious. These include treating individual neurons
as the experimental unit, which is common in elec-
trophysiological studies, but just as inappropriate
as treating blood pressure values taken from left
and right arms as n = 2, or dissecting a single liver
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sample into ten pieces and treating the expression
of a gene measured in each piece as n = 10 [12]. If
it were that easy, clinical trials could be conducted
with tens of patients rather than hundreds or thou-
sands. Regulatory authorities are not fooled by such
stratagems, but is seems many journal editors and
peer-reviewers are. A list of studies can be found in
Additional File 3.
Estimating the magnitude of litter effects
To illustrate the extent to which litter effects can
influence the results, data originally published by
Mehta et al. [41] were used and experimental de-
tails can be found therein. Locomotor activity in
the open field is shown in Figure 2 for nine VPA
and five saline injected control litters. Half of the
animals from each condition were given MPEP (a
mGluR5 receptor antagonist) or saline. Visually,
there do not appear to be differences between VPA
and control groups and there is a slight increase in
activity due to MPEP. The effect of MPEP was not
significant when litter effects were ignored (Figure
2A; p = 0.082), but it was when adjusting for litter
(Figure 2B; p = 0.011). In this case the shift in
p-value was not large, but it happened to decrease
it below the 0.05 threshold after the excess noise
caused by litter-to-litter variation was removed.
It may be difficult to determine whether litter ef-
fects are present by simply plotting the data by litter
because they may be obscured by the experimental
effects. For a visual check, it is preferable to remove
the effect of the experimental factors first and then
plot the residual values versus litter. The y-axis
for Figure 3 shows the residuals, which are defined
as the difference between the observed locomotor
activity for each animal and the value predicted
from the model containing group (VPA/saline) and
condition (MPEP/saline) as factors (from Figure
2A). The residuals should be pure noise, centred at
zero, and should not be associated with any other
variable. However, it is clear that there are large
differences between litters (Figure 3A), indicating
heterogeneity in the response from one litter to the
next. When litter effects are taken into account,
the mean of each litter is closer to zero. Also note
that variance of the residuals (σ2 ) is reduced by 61%
when litter is taken into account (p < 0.001). This
is shown by the spread of the grey points around
zero on the right side of each graph, which are clus-
tered closer together in the second analysis. The
interpretation is that litter accounted for 61% of the
previously unexplained variation in the data. Note
that it would be impossible to determine whether
litter effects are present if only one litter per treat-
ment group was used because litter and treatment
would be completely confounded.
A similar analysis was performed for other vari-
ables and the results are displayed in Table 1. It is
clear that litter-to-litter variation is important for
a number of behavioural outcomes. It is also clear
from Figure 3A how one could obtain false positives
with an inappropriate design and analysis. Suppose
an experiment was conducted with only one VPA
and one saline litter, with ten animals from each,
and that there is no overall effect of VPA on a par-
ticular outcome. If the experimenter happened to
select Litter A (saline) and Litter M (VPA) there
would be a significant increase due to VPA, but if
Litter D (saline) and Litter G (VPA) were selected,
there would be a significant effect in the opposite
direction! There are many combinations of a single
saline and VPA litter that would lead to a signifi-
cant difference between conditions. Having two or
three litters per group instead of one will reduce the
false positive rate, but it will still be much higher
than 0.05 [4]. In addition, these apparent differences
would not replicate with a properly designed follow-
up experiment.
How power is affected by the number of litters
and animals
Figure 4 shows the power for various combinations
of number of litters and number of animals per lit-
ter. This analysis is based on averaging the values
for the animals within a litter and then comparing
the groups with a t-test. It is clear that increasing
the number of animals per litter has little effect on
power (the lines in Figure 4A are nearly flat after
two animals per litter), whereas increasing the num-
ber of litters results in a large increase in power.
The results for the mixed-effect model are nearly
identical and the results of the inappropriate analy-
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sis which ignores litter shows increasing power with
increasing number of animals per litter (Additional
File 4). This is false power however, and is due to an
artificially inflated sample size (pseudoreplication)
that will lead to many false positive results.
Some may object on ethical grounds to using so
many litters and then selecting only one or a few
animals from each, as there will be many additional
animals that will not be used and presumably culled.
Certainly all of the animals could be used, but there
is almost no increase in power after three animals
per litter (at least for the locomotor data) and there-
fore it is a poor use of time and resources to include
all of the animals. One could argue therefore that it
is unethical to submit a greater number of animals
to the experimental procedure if they contribute lit-
tle or nothing to the result. One could also argue
that it is even more unethical to use any animals
for a severely underpowered (or flawed) study in the
first place and then to clutter the scientific literature
with the results. One way to deal with the excess
animals is to use them for other experiments. This
requires greater planning, organisation, and coor-
dination, but it is possible. Another option is to
purchase animals from a commercial supplier and
request that the animals come from different litters
rather than have an in-house colony. As a side note,
suppliers do not routinely provide information on
the litters that the animals came from and thus an
important variable is not under the experimenter’s
control and cannot even be checked whether it is
influencing the results.
How does litter-to-litter variation arise?
Differences between litters could exist for a variety
of reasons, including shared genes and shared prena-
tal and early postnatal environments, but also due
to age differences (it is difficult to control the time of
mating), and because litters are convenient units to
work with. For example, it is not unusual for litter-
mates to be housed in the same cage, which means
that animals within a litter also share not just their
early, but also their adult environment. It is also
often administratively easier to apply experimental
treatments on a per cage (and thus per litter) basis
rather than per animal basis. For example, animals
in cage A and C are treated while cage B and D
are controls. Animals may also undergo behavioural
testing on a per cage basis; for example, animals are
taken from the housing room to the testing room one
cage at a time, tested, and then returned. Larger
experiments may need to be conducted over several
days and it is often easier to test all the animals in
a subset of cages on each day, rather than a subset
of animals from all of the cages. At the end of the
experiment animals may also be killed on a per cage
basis. Given that it may take many hours to kill
the animals, remove the brains, collect blood, etc.,
the values of many outcomes such as gene expres-
sion, hormone and metabolite concentrations, and
physiological parameters may change due to circa-
dian rhythms. All of these can lead to systematic
differences between litters and can thus bias results
and/or add noise to the data.
There is an important distinction to be made
between applying treatments to whole litters versus
“natural” variation between litters. When a treat-
ment is applied to a whole litter such as the VPA
model of autism or maternal stress models, then the
litter is the experimental unit and the sample size is
the number of litters. Therefore, by definition, litter
needs to be included in the analysis if more than one
animal per litter is used (or the values within a litter
can be averaged). However, if multiple litters are
used but the treatment(s) are applied to the individ-
ual animals, experiments should be designed so that
if litter effects exist, then valid inferences can still
be made. In other words, litters should not be con-
founded with other experimental variables because
it would be difficult or impossible to detect their
influence and remove their effects. Whether litter
is an important factor for any particular outcome is
then an empirical question, and if it is not impor-
tant then it need not be included in the analysis.
However, the power to detect differences between
litters will be low if only a few litters are used in
the experiment and therefore a non-significant test
for litter effects should not be interpreted as the ab-
sence of such effects. Analysing the data with and
without litter and choosing the analysis that gives
the “right” answer should of course be avoided [35].
Flood et al. provide a nice example in the autism
literature of an appropriate design followed by a
check for litter effects, and then the results for the
experimental effect were reported when litter was
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both included and excluded [47]. Consistent with
other studies demonstrating litter-effects, this paper
found a strong effect of litter on brain mass.
Four ways to improve basic and translational re-
search
Better training for biologists
Most experimental biologists are not provided with
sufficient training in experimental design and data
analysis to be able to plan, conduct, and interpret
the results of scientific investigations at the level re-
quired to consistently obtain valid results. The solu-
tion is straightforward, but requires major changes
in the education and training of biologists and it
will take many years to implement. Nevertheless,
this should be a long-term goal for the biomedical
research community.
Make better use of statistical expertise
A second solution is to have statisticians play a
greater role in preclinical studies, including peer
reviewing grant applications and manuscripts, as
well as being part of scientific teams [48]. However,
there are not enough statisticians with the appro-
priate subject matter knowledge to fully meet this
demand—just as it is difficult to do good science
without a knowledge of statistics, it is difficult to
perform a good analysis without knowledge of the
science. In addition, this type of “project support”
is often viewed by academic statisticians as a sec-
ondary activity. Despite this, there is still scope for
improving the quality of studies by making better
use of statistical expertise.
More detailed reporting of experimental methods
Detailed reporting of how experiments were con-
ducted, how data were analysed, how outliers were
handled, whether all animals that entered the study
completed it, and how the sample size was deter-
mined are all required to assess whether the results
of the study are valid, and a number of guidelines
have been proposed which cover these points, includ-
ing the National Institute of Neurological Disorders
and Stroke (NINDS) guidelines [49], the Gold Stan-
dard Publication Checklist [50], and the ARRIVE
(Animals in Research: Reporting In Vivo Experi-
ments) guidelines [51]. For example, ARRIVE items
6 (Study design), 10 (Sample size), 11 (Allocating
animals to experimental groups), and 13 (Statisti-
cal methods) should a be mandatory requirement
for all publications involving animals and could be
included as a separate checklist that is submitted
along with the manuscript, much like a conflict of
interest or a transfer of copyright form. Something
similar has recently been introduced by Nature Neu-
roscience [52]. This would make it easier to spot any
design and analysis issues by reviewers, editors, and
other readers. In addition, and more importantly, if
scientists are required to comment on how they ran-
domised treatment allocation, or how they ensured
that assessment of outcomes was blinded, then they
will conduct their experiments accordingly if they
plan on submitting to a journal with these reporting
requirements. Similarly, if researchers are required
to state what the experimental unit is (e.g. litter,
cage, individual animal, etc.), then they will be
prompted to think hard about the issue and design
better experiments, or seek advice. This recommen-
dation will not only improve the quality of reporting,
but it will also improve the quality of experiments,
which is the real benefit. A final advantage is that it
will make quantitative reviews/meta-analyses easier
because much of the key information will be on a
single page.
Make raw data available
Another solution is to make the provision of raw
data a requirement for acceptance of a manuscript;
not “to make it available if someone asks for it”,
which is the current requirement for many journals,
but uploaded as supplementary material or hosted
by a third party data repository. None of the VPA
studies provided the data that the conclusions were
based on, making reanalysis impossible. Remark-
ably, of the thirty-five studies published, only one
provided the necessary information to conduct a
power analysis to plan a future study [46], and this
was only because one animal per litter was used and
the necessary values could be extracted from the fig-
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ures. Datasets used in preclinical animal studies are
typically small, do not have confidentiality issues
associated with them, are unlikely to be used for
further analyses by the original authors, and have
no additional intellectual property issues associated
with them given that the manuscript itself has been
published. It is noteworthy that many journals re-
quire microarray data to be uploaded to a publicly
available repository (e.g. Gene Expression Omnibus
or ArrayExpress), but not the corresponding be-
havioural or histological data. It is perhaps not
surprising that there is a relationship between study
quality and the willingness to share data [53–55].
Publishing raw data can be taken as a signal that
researchers stand behind their data and therefore
their conclusions. Funding bodies should encourage
this by requiring that data arising from the grant
are made publicly available (with penalties for non-
adherence).
The above suggestions would help ensure that
appropriate design and analyses were used, and to
make it easy to verify claims or to reanalyse data.
Currently, it is often difficult to establish the for-
mer and almost impossible to perform the latter.
Moreover, it is clear that appropriate designs and
analyses are often not used, making it difficult to
give the benefit of the doubt to those studies with
incomplete reporting of how experiments were con-
ducted and data analysed.
Conclusions
While it is difficult to quantify the extent to which
poor statistical practices hinder basic and transla-
tional research, it is clear that a large inflation of
false positive and false negative rates will only slow
progress. In addition, because of publication bias
and researcher degrees of freedom, it is possible for a
field to converge to the wrong answer. Experimental
design and statistical issues are, in principle, fixable.
Improving these will allow scientists to focus on cre-
ating and assessing the suitability of disease models
and the efficacy of therapeutic interventions, which
is challenging enough.
List of abbreviations
ANOVA: analysis of variance; BP: blood pressure;
MPEP: 2-methyl-6-phenylethyl-pyrididine; SOD1:
superoxide dismutase; VPA: valproic acid
Authors contributions
SEL planned and carried out the study, performed
the literature search and analysis, and wrote the pa-
per. LE provided constructive input. All authors
read and approved the final manuscript.
Competing interests
The author declares no competing interests.
Acknowledgements
The authors would like to thank the Siegel lab at the
University of Pennsylvania for kindly sharing their data.
References
1. Geerts H: Of mice and men: bridging the trans-
lational disconnect in CNS drug discovery. CNS
Drugs 2009, 23(11):915–926, [http://dx.doi.org/10.2165/
11310890-000000000-00000].
2. Haseman JK, Hogan MD: Selection of the experi-
mental unit in teratology studies. Teratology 1975,
12(2):165–171.
3. Hughes CW: Outcome of early experience studies
as affected by between-litter variance. J Nutr 1979,
109(4):642–645.
4. Holson RR, Pearce B: Principles and pitfalls in the
analysis of prenatal treatment effects in multi-
parous species. Neurotoxicol Teratol 1992, 14(3):221–
228.
5. Zorrilla EP: Multiparous species present problems
(and possibilities) to developmentalists. Dev Psy-
chobiol 1997, 30(2):141–150.
6. Wainwright PE: Issues of design and analysis relat-
ing to the use of multiparous species in develop-
mental nutritional studies. J Nutr 1998, 128(3):661–
663.
7. Festing MFW, Altman DG: Guidelines for the design
and statistical analysis of experiments using lab-
oratory animals. ILAR J 2002, 43(4):244–258.
8. Festing MFW: Principles: the need for better
experimental design. Trends Pharmacol Sci 2003,
24(7):341–345.
9. Festing MFW: Design and statistical methods in
studies using animal models of development. ILAR
J 2006, 47:5–14.
10. Casella G: Statistical Design. New York : Springer 2008.
9
11. Maurissen J: Practical considerations on the design,
execution and analysis of developmental neuro-
toxicity studies to be published in Neurotoxi-
cology and Teratology. Neurotoxicol Teratol 2010,
32(2):121–123, [http://dx.doi.org/10.1016/j.ntt.2009.09.
002].
12. Lazic SE: The problem of pseudoreplication in neu-
roscientific studies: is it affecting your analysis?
BMC Neurosci 2010, 11:5, [http://dx.doi.org/10.1186/
1471-2202-11-5].
13. International Conference on Harmonisation: Detection
of toxicity to reproduction for medicinal products
and toxicity to male fertility. S5(R2) 1993.
14. OECD: Guideline for the testing of chem-
icals: developmental neurotoxicity study
2007, :1–26, [http://www.oecd-ilibrary.org/
test-no-426-developmental-neurotoxicity-study
5l4fg25mnkxs.pdf;jsessionid=12ic71yg7bopl.delta?
contentType=/ns/Book&itemId=/content/book/
9789264067394-en&containerItemId=/content/serial/
20745788&accessItemIds=&mimeType=application/
pdf].
15. Hurlbert SH: Pseudoreplication and the design
of ecological field experiments. Ecol Monogr 1984,
54(2):187–211.
16. Schnabel J: Neuroscience: Standard model. Na-
ture 2008, 454(7205):682–685, [http://dx.doi.org/10.
1038/454682a].
17. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K,
Kelly N, Bostrom A, Theodoss J, Al-Nakhala BM, Vieira
FG, Ramasubbu J, Heywood JA: Design, power, and
interpretation of studies in the standard murine
model of ALS. Amyotroph Lateral Scler 2008, 9:4–15,
[http://dx.doi.org/10.1080/17482960701856300].
18. Benatar M: Lost in translation: treatment trials in
the SOD1 mouse and in human ALS. Neurobiol Dis
2007, 26:1–13, [http://dx.doi.org/10.1016/j.nbd.2006.12.
015].
19. Bebarta V, Luyten D, Heard K: Emergency medicine
animal research: does use of randomization and
blinding affect the results? Acad Emerg Med 2003,
10(6):684–687.
20. Crossley NA, Sena E, Goehler J, Horn J, van der Worp
B, Bath PMW, Macleod M, Dirnagl U: Empirical
evidence of bias in the design of experimental
stroke studies: a metaepidemiologic approach.
Stroke 2008, 39(3):929–934, [http://dx.doi.org/10.1161/
STROKEAHA.107.498725].
21. Kilkenny C, Parsons N, Kadyszewski E, Festing MFW,
Cuthill IC, Fry D, Hutton J, Altman DG: Survey
of the quality of experimental design, statisti-
cal analysis and reporting of research using an-
imals. PLoS One 2009, 4(11):e7824, [http://dx.doi.org/
10.1371/journal.pone.0007824].
22. Sena ES, van der Worp HB, Bath PMW, Howells DW,
Macleod MR: Publication bias in reports of animal
stroke studies leads to major overstatement of ef-
ficacy. PLoS Biol 2010, 8(3):e1000344, [http://dx.doi.
org/10.1371/journal.pbio.1000344].
23. Vesterinen HM, Sena ES, ffrench Constant C, Williams
A, Chandran S, Macleod MR: Improving the trans-
lational hit of experimental treatments in multi-
ple sclerosis. Mult Scler 2010, 16(9):1044–1055, [http:
//dx.doi.org/10.1177/1352458510379612].
24. Hackam DG, Redelmeier DA: Translation of re-
search evidence from animals to humans. JAMA
2006, 296(14):1731–1732, [http://dx.doi.org/10.1001/
jama.296.14.1731].
25. Dirnagl U: Bench to bedside: the quest for qual-
ity in experimental stroke research. J Cereb Blood
Flow Metab 2006, 26(12):1465–1478, [http://dx.doi.org/
10.1038/sj.jcbfm.9600298].
26. Philip M, Benatar M, Fisher M, Savitz SI: Method-
ological quality of animal studies of neuropro-
tective agents currently in phase II/III acute
ischemic stroke trials. Stroke 2009, 40(2):577–581,
[http://dx.doi.org/10.1161/STROKEAHA.108.524330].
27. Bart van der Worp H, Howells DW, Sena ES, Porritt
MJ, Rewell S, O’Collins V, Macleod MR: Can animal
models of disease reliably inform human studies?
PLoS Med 2010, 7(3):e1000245, [http://dx.doi.org/10.
1371/journal.pmed.1000245].
28. Shineman DW, Basi GS, Bizon JL, Colton CA, Green-
berg BD, Hollister BA, Lincecum J, Leblanc GG, Lee
LBH, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR,
Scearce-Levie K, Sweeney P, Yrjanheikki J, Fillit HM:
Accelerating drug discovery for Alzheimer’s dis-
ease: best practices for preclinical animal studies.
Alzheimers Res Ther 2011, 3(5):28, [http://dx.doi.org/
10.1186/alzrt90].
29. Rooke EDM, Vesterinen HM, Sena ES, Egan KJ,
Macleod MR: Dopamine agonists in animal mod-
els of Parkinson’s disease: a systematic re-
view and meta-analysis. Parkinsonism Relat Dis-
ord 2011, 17(5):313–320, [http://dx.doi.org/10.1016/j.
parkreldis.2011.02.010].
30. Sarewitz D: Beware the creeping cracks of bias.
Nature 2012, 485(7397):149, [http://dx.doi.org/10.1038/
485149a].
31. Nieuwenhuis S, Forstmann BU, Wagenmakers EJ: Er-
roneous analyses of interactions in neuroscience:
a problem of significance. Nat Neurosci 2011,
14(9):1105–1107, [http://dx.doi.org/10.1038/nn.2886].
32. Cumming G, Fidler F, Vaux DL: Error bars in exper-
imental biology. J Cell Biol 2007, 177:7–11.
33. Lazic SE: Relating hippocampal neurogenesis to
behavior: the dangers of ignoring confound-
ing variables. Neurobiol Aging 2010, 31(12):2169–
2171, [http://dx.doi.org/10.1016/j.neurobiolaging.2010.
04.037].
34. Lazic SE: Using causal models to distinguish be-
tween neurogenesis-dependent and -independent
effects on behaviour. J R Soc Interface 2011; e-pub
ahead of print 28 Sep 2011; doi:101098/rsif20110510,
[http://dx.doi.org/10.1098/rsif.2011.0510].
35. Simmons JP, Nelson LD, Simonsohn U: False-positive
psychology: undisclosed flexibility in data collec-
tion and analysis allows presenting anything as
significant. Psychol Sci 2011, 22(11):1359–1366, [http:
//dx.doi.org/10.1177/0956797611417632].
10
36. Mullard A: Reliability of ’new drug target’ claims
called into question. Nat Rev Drug Discov 2011,
10(9):643–644, [http://dx.doi.org/10.1038/nrd3545].
37. Prinz F, Schlange T, Asadullah K: Believe it or not:
how much can we rely on published data on po-
tential drug targets? Nat Rev Drug Discov 2011,
10(9):712, [http://dx.doi.org/10.1038/nrd3439-c1].
38. Ledford H: Drug candidates derailed in case of
mistaken identity. Nature 2012, 483(7391):519, [http:
//dx.doi.org/10.1038/483519a].
39. Begley CG, Ellis LM: Drug development: Raise
standards for preclinical cancer research. Na-
ture 2012, 483(7391):531–533, [http://dx.doi.org/10.
1038/483531a].
40. Rinaldi T, Silberberg G, Markram H: Hyperconnec-
tivity of local neocortical microcircuitry induced
by prenatal exposure to valproic acid. Cereb Cortex
2008, 18(4):763–770, [http://dx.doi.org/10.1093/cercor/
bhm117].
41. Mehta MV, Gandal MJ, Siegel SJ: mGluR5-antagonist
mediated reversal of elevated stereotyped, repet-
itive behaviors in the VPA model of autism.
PLoS One 2011, 6(10):e26077, [http://dx.doi.org/10.
1371/journal.pone.0026077].
42. Zuur AF, Ieno EN, Walker NJ, Saveliev AA, Smith GM:
Mixed Effects Models and Extensions in Ecology with R.
New York: Springer 2009.
43. Gelman A, Hill J: Data Analysis using Regression and
Multilevel/Hierarchical Models. Cambridge, UK: Cam-
bridge University Press 2007.
44. Stodgell CJ, Ingram JL, O’Bara M, Tisdale BK, Nau H,
Rodier PM: Induction of the homeotic gene Hoxa1
through valproic acid’s teratogenic mechanism of
action. Neurotoxicol Teratol 2006, 28(5):617–624, [http:
//dx.doi.org/10.1016/j.ntt.2006.08.004].
45. Kuwagata M, Ogawa T, Shioda S, Nagata T: Obser-
vation of fetal brain in a rat valproate-induced
autism model: a developmental neurotoxicity
study. Int J Dev Neurosci 2009, 27(4):399–405, [http:
//dx.doi.org/10.1016/j.ijdevneu.2009.01.006].
46. Murawski NJ, Brown KL, Stanton ME: Interstimulus
interval (ISI) discrimination of the conditioned
eyeblink response in a rodent model of autism.
Behav Brain Res 2009, 196(2):297–303, [http://dx.doi.
org/10.1016/j.bbr.2008.09.020].
47. Flood ZC, Engel DLJ, Simon CC, Negherbon KR,
Murphy LJ, Tamavimok W, Anderson GM, Janusonis
S: Brain growth trajectories in mouse strains
with central and peripheral serotonin differences:
relevance to autism models. Neuroscience 2012,
210:286–295, [http://dx.doi.org/10.1016/j.neuroscience.
2012.03.010].
48. Peers IS, Ceuppens PR, Harbron C: In search of
preclinical robustness. Nat Rev Drug Discov 2012,
11(10):733–734, [http://dx.doi.org/10.1038/nrd3849].
49. Landis SC, Amara SG, Asadullah K, Austin CP, Blu-
menstein R, Bradley EW, Crystal RG, Darnell RB, Fer-
rante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman
HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK,
Hesterlee SE, Howells DW, Huguenard J, Kelner K, Ko-
roshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR,
McCall JM, Moxley RT, Narasimhan K, Noble LJ, Per-
rin S, Porter JD, Steward O, Unger E, Utz U, Silber-
berg SD: A call for transparent reporting to opti-
mize the predictive value of preclinical research.
Nature 2012, 490(7419):187–191, [http://dx.doi.org/10.
1038/nature11556].
50. Hooijmans CR, Leenaars M, Ritskes-Hoitinga M: A gold
standard publication checklist to improve the
quality of animal studies, to fully integrate the
Three Rs, and to make systematic reviews more
feasible. Altern Lab Anim 2010, 38(2):167–182.
51. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Alt-
man DG: Improving bioscience research report-
ing: the ARRIVE guidelines for reporting ani-
mal research. PLoS Biol 2010, 8(6):e1000412, [http:
//dx.doi.org/10.1371/journal.pbio.1000412].
52. Making methods clearer. Nat Neurosci 2013, 16:1,
[http://dx.doi.org/10.1038/nn0113-1].
53. Wicherts JM, Borsboom D, Kats J, Molenaar D: The
poor availability of psychological research data
for reanalysis. Am Psychol 2006, 61(7):726–728, [http:
//dx.doi.org/10.1037/0003-066X.61.7.726].
54. Bakker M, Wicherts JM: The (mis)reporting of
statistical results in psychology journals. Behav
Res Methods 2011, 43(3):666–678, [http://dx.doi.org/10.
3758/s13428-011-0089-5].
55. Wicherts JM, Bakker M, Molenaar D: Willingness to
share research data is related to the strength of
the evidence and the quality of reporting of sta-
tistical results. PLoS One 2011, 6(11):e26828, [http:
//dx.doi.org/10.1371/journal.pone.0026828].
11
Figures
Figure 1 - Defining the experimental unit
Pregnant females are the experimental units because they are randomised to the treatment (e.g. valproic
acid) or control conditions and therefore n = 6 in this example. The three offspring within a litter will often
be more alike than offspring from different litters
(
Between litter variation
Within litter variation > 1
)
and multiple offspring within
a litter can be thought of as subsamples or “technical replicates”, even though these are the scientific unit
of interest. Only the mean of the within-litter values are important when comparing treated and control
groups. Using all of the offspring without averaging will result in an inflated sample size (pseudoreplication)
with standard statistical analyses. Instead of averaging, one could randomly select only one animal from
each litter, or use a mixed-effects model to appropriately partition the different sources of variation. The
only way to increase sample size, and thus power, is to increase the number of litters used.
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Figure 2 - Analysis with and without litter taken into account
Nine pregnant female C57BL/6 mice were injected with 600 mg/kg VPA subcutaneously on embryonic day
13, and five control females received vehicle injections. Half of the animals in each condition were also
injected with either a mGluR5 receptor antagonist (MPEP) or saline postnatally. Total locomotor activity
in the open field over a 30 min period at 8–9 weeks of age is shown. There was a slight increase in activity
due to MPEP, but it was not significant when differences between litters were ignored (A; two-way ANOVA,
mean difference = 0.60, F(1,44) = 3.17, p = 0.082). Adjusting for litter removed unexplained variation in
the data, allowing the small difference between groups to become statistically significant (B; mixed-effects
model, mean difference = 0.64, F(1,32) = 7.19, p = 0.011). Note how the values in the second graph have
less variability around the group means; this increased precision leads to greater power of the statistical
tests. Lines go through the mean of each group and points are jittered in the x direction.
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Figure 3 - Visualising litter-to-litter variation
The residuals represent the unexplained variation in the data after the effects of VPA and MPEP have
been taken into account; they should be pure noise and therefore not associated with any other variable.
However, the standard analysis (A) shows that when residuals are plotted against litter (x-axis) there are
large differences between litters. In other words, there is another factor affecting the outcome besides the
experimental factors of interest. The variance of the residuals (grey points on the right) is high (σ2 = 1.29).
The proper analysis (B) reduces the unexplained variation in the data by 61% (σ2 = 0.50; p < 0.001), which
can be seen by the narrower spread of the grey points around zero, and the large differences between the
litters have been removed. This reduction in noise allows smaller true signals to be detected. Error bars are
SEM. Litters F and L only have one observation and thus no error bars.
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Figure 4 - Power calculations for VPA experiments
Panel A shows how power changes as the number of animals per litter increases from one to eight (x-axis)
and the number of litters per group increases from three to ten (different lines). It is clear that increasing the
number of animals per litter has only a modest effect on power with little improvement after two animals. A
two-group study with three litters per group and eight animals per litter (2× 3× 8 = 48 animals) will have
only a 30% chance of detecting the effect, whereas a study with ten litters per group and one animal per
litter (2× 10× 1 = 20 animals) will have almost 80% power and also use far fewer animals. Panel B shows
the same data, but presented differently. Power for different combinations of litters and animals per litter
is indicated by colour (red = low power, white = high) and reference lines for 70%, 80%, and 90% power
are indicated. Note that these specific power values are only relevant for the locomotor activity task with a
fixed effect size and will have to be recalculated for other outcomes. However, the general result (increasing
litters is better than increasing the number of animals per litter) will apply for all outcomes.
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Tables
Table 1 - Importance of litter effects on body weight and behavioural tests.
The p-value tests whether the litter-to-litter variation was significantly greater than zero.
Variable Reduction in σ2 P-value
Locomotor activity 61% <0.001
Body weight 50% 0.003
Marbles buried 38% 0.045
Anxiety (open field) 35% 0.0504
Grooming 23% 0.116
σ2 is the residual (unexplained) variation.
Additional Files
Additional file 1 — R code for the analyses and power calculations
Code for the analyses and power calculations are given as a plain text file.
Additional file 2 — Raw data
Raw data from Mehta et al. [41], including body weight, locomotor activity and anxiety measures from the
open field test, grooming behaviour, and number of marbles buried in the marble-burying test. Details can
be found in the original publication.
Additional file 3 — List of VPA studies
List of the thirty-four studies using the VPA rodent model of autism.
Additional file 4 — Power analysis for the mixed-effects model and the incorrect analysis
The interpretation of the graphs is the same as Figure 4 (main text). Panels A and B are for the mixed-effects
model and are nearly identical to the results for averaging the values within each litter and then using a
t-test (Figure 4 main text). Panels C and D ignore litter and compare all of the data with a t-test, which
results in an artificially inflated sample size and inappropriately high power.
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